BAAM
ALNY icon

Baker Avenue Asset Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Baker Avenue Asset Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-10
Closed -$1.77K – 412
2023
Q3 		$1.77K Buy
10
+3
+43% +$572 ﹤0.01% 1156
2023
Q2 		$1.33K Sell
7
-2
-22% -$397 ﹤0.01% 1089
2023
Q1 		$1.8K Sell
9
-5
-36% -$1.05K ﹤0.01% 1014
2022
Q4 		$3.33K Buy
+14
New +$2.99K ﹤0.01% 866

Other funds holding ALNY

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Baker Avenue Asset Management's ALNY Position: Q4 2023 in Review

Baker Avenue Asset Management sold out of Alnylam Pharmaceuticals (ALNY) in Q4 2023, closing a stake of 10 shares — an estimated $1.77K sold.

Baker Avenue Asset Management first reported a position in ALNY in Q4 2022 and held it in 4 quarters. The position peaked at $3.33K in Q4 2022. 499 funds tracked by Wall St. Rank hold ALNY as of Q4 2023.

  • Baker Avenue Asset Management reported no remaining Alnylam Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Baker Avenue Asset Management sold 10 Alnylam Pharmaceuticals shares in Q4 2023, an estimated $1.77K.
  • Baker Avenue Asset Management first reported a position in Alnylam Pharmaceuticals in Q4 2022 and held it in 4 quarters.
  • Baker Avenue Asset Management's Alnylam Pharmaceuticals position peaked at $3.33K in Q4 2022.
  • 499 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2023.

Based on Baker Avenue Asset Management's 13F filing for Q4 2023, filed 13 Feb 2024.